Tiba biotech, LLC - AOI#25(FASTX) R & D for respiratory virus treatment using lung-targeted sirna delivery
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50124C00014
- Awardee
-
Tiba Biotech LLC UEI XNL9ZSLHN795
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $726,389
Award facts
- Opportunity
-
- BAA22100SOL00003 Solicitation number
- Contract value 100% obligated
- $726,389.15 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- 1 offer Basic Research
- Pricing
- Firm Fixed Price
- Place of performance
- Cambridge, MA 02142, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$23,610 | |
| Terminate for Convenience | $0 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Original award | $749,999 |
About this award
The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR), awarded a $726,389 firm fixed-price contract to Tiba Biotech LLC on April 30, 2024, for research and development of a respiratory virus treatment utilizing lung-targeted small interfering RNA (siRNA) delivery systems. The contract, which carries no set-aside designation, is scheduled for completion by August 5, 2025. This award falls under the ASPR's mission to enhance the nation's preparedness and response capabilities for public health emergencies, including infectious disease threats.
Tiba Biotech LLC, a Cambridge, Massachusetts-based biotechnology company, specializes in advanced RNA delivery platforms and vaccine technologies. The company brings significant expertise in dendrimer-based nanoparticle systems designed to optimize RNA content delivery, protect nucleic acids from degradation, and facilitate efficient cellular uptake. This contract aligns with Tiba Biotech's established track record of federal funding, including prior grants from the National Institute of Allergy and Infectious Diseases and the National Cancer Institute for innovative RNA vaccine development. The firm's capabilities in rapid-response platform development position it well to advance therapeutic options for respiratory virus treatment, supporting ASPR's preparedness objectives.
Quick answers
Who was awarded contract 75A50124C00014?
75A50124C00014 was awarded to Tiba Biotech LLC by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on April 30, 2024.
How much is contract 75A50124C00014 worth?
The government has obligated $726,389 on 75A50124C00014.
Was contract 75A50124C00014 competed?
The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award